Department of Biomedical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Osogbo Campus, Nigeria.
Int J Antimicrob Agents. 2011 Jan;37(1):62-6. doi: 10.1016/j.ijantimicag.2010.08.019. Epub 2010 Nov 11.
In Nigeria, quinolones and β-lactam antibiotics are widely used to treat bacterial infections. This study aimed to identify the prevalence of resistance to these drugs and to determine the mechanisms of resistance to these agents. In total, 134 non-duplicate, Gram-negative enteric isolates of 13 species from different hospitals were investigated for susceptibility to a panel of antibiotics, carriage of plasmid-mediated quinolone and β-lactam resistance genes, production of extended-spectrum β-lactamases (ESBLs), and mutations within topoisomerase genes. The level of resistance to all antibiotics tested was extremely high, with minimum inhibitory concentrations for 90% of the organisms (MIC(90) values) of ≥ 256 μg/mL for all drugs. Of the 134 isolates, 92 had mutations within the quinolone resistance-determining region (QRDR) of gyrA or within gyrA and parC. In addition, the plasmid-mediated quinolone resistance genes qnrA, qnrB, aac(6')-Ib-cr and qepA were identified. The qnrD allele, which has previously only been found in Salmonella isolates from China, was identified in two Proteus isolates and one Pseudomonas isolate. Of the 134 isolates, 23 (17.2%) carried aac(6')-Ib-cr, 11 (8.2%) carried a qnr variant and 5 (3.7%) were positive for qepA. Twenty-eight isolates (20.9%) produced ESBL variants, with a CTX-M variant being carried by 25 isolates (18.7%). In addition, six isolates (4.5%) carried ampC variants [ACT-1 (1 isolate), DHA-1 (4 isolates) and CMY-2 (1 isolate)]. This study demonstrates a very high level of multidrug resistance amongst Gram-negative enteric bacilli isolated from different sites from patients in Nigerian hospitals as well as the presence of a variety of plasmid-associated resistance genes, including some identified from Africa for the first time.
在尼日利亚,喹诺酮类和β-内酰胺类抗生素被广泛用于治疗细菌感染。本研究旨在确定这些药物耐药的流行率,并确定这些药物耐药的机制。总共从不同医院的 13 个种的 134 个非重复革兰氏阴性肠杆菌分离株调查了对一组抗生素的敏感性,携带质粒介导的喹诺酮类和β-内酰胺类耐药基因,产超广谱β-内酰胺酶(ESBLs)以及拓扑异构酶基因内的突变。所有测试抗生素的耐药水平极高,所有药物的 90%的生物体的最小抑菌浓度(MIC(90)值)均≥256μg/ml。在 134 个分离株中,92 个具有 gyrA 或 gyrA 和 parC 内的喹诺酮类耐药决定区(QRDR)内的突变。此外,还鉴定了质粒介导的喹诺酮类耐药基因 qnrA、qnrB、aac(6')-Ib-cr 和 qepA。qnrD 等位基因以前仅在中国分离的沙门氏菌中发现,在两个变形杆菌和一个假单胞菌中发现。在 134 个分离株中,23 个(17.2%)携带 aac(6')-Ib-cr,11 个(8.2%)携带 qnr 变体,5 个(3.7%)对 qepA 呈阳性。28 个分离株(20.9%)产生 ESBL 变体,25 个分离株(18.7%)携带 CTX-M 变体。此外,6 个分离株(4.5%)携带 ampC 变体[ACT-1(1 个分离株)、DHA-1(4 个分离株)和 CMY-2(1 个分离株)]。本研究表明,从尼日利亚医院的不同部位的患者分离的革兰氏阴性肠杆菌中存在非常高水平的多药耐药性,以及存在多种质粒相关的耐药基因,包括一些首次从非洲鉴定出的耐药基因。